Scarica l'app Stockscreener
31.17
0.67%
-0.21
Pre-mercato:
30.67
-0.50
-1.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Bank of New York Mellon Corp Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - Stock Traders Daily
Smartleaf Asset Management LLC Has $47,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Proficio Capital Partners LLC Acquires Shares of 11,282 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Spectrum Brands Holdings, Inc. (SPB): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus to Participate in Two Upcoming Investor Conferences - GlobeNewswire
CNS Specialist Supernus Sets Investor Conference ScheduleWill You Hear What the CEO Has to Say? - StockTitan
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses - accessnewswire.com
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? - Yahoo Finance
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now? - Yahoo Finance
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Supernus Pharmaceuticals’ (SUPN) “Neutral” Rating Reiterated at Cantor Fitzgerald - Defense World
StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy - Defense World
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus.com
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
What Questions Should Investors Ask Supernus CEO at Upcoming TD Cowen Conference? - StockTitan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Rhumbline Advisers - Defense World
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Enters Oversold Territory (SUPN) - Nasdaq
Supernus Pharmaceuticals Inc (SUPN) Reports Q4 2024 EPS of $0.27 - GuruFocus.com
Cantor maintains neutral on Supernus, price target at $36 By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2024 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance - Marketscreener.com
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates - Investing.com India
Supernus Pharmaceuticals Exceeds Q4 2024 Revenue ExpectationsNews and Statistics - IndexBox, Inc.
Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Supernus: Q4 Earnings Snapshot - Huron Daily Tribune
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Supernus' depression treatment fails mid-stage trial, shares plunge - MSN
Earnings call transcript: Supernus Q4 2024 revenue beats expectations - Investing.com
Unveiling the Enigma: Supernus Pharmaceuticals Shatters Expectations Yet Faces Uncertainty - Mi Valle
Earnings call transcript: Supernus Q4 2024 revenue beats expectations By Investing.com - Investing.com UK
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers By Stock Story - Investing.com Canada
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers - Yahoo Finance
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates By Investing.com - Investing.com South Africa
Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q4 Revenue $174.2M, vs. FactSet Est of $155.3M - Marketscreener.com
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
0.77%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):